Genentech, Inc.

Constellation Pharmaceuticals, Inc.

F. Hoffmann-la Roche Ag

James Richard Kiefer, Jr

Naomi S Rajapaksa

Marian C Bryan

Jun Liang

Joy Drobnick

Alberto Gobbi

Tamiko Katsumoto

Steven Huy Do

Aleksandr Kolesnikov

Kwong Wah Lai

Liqiang Fu

Fei Wang

Jean-Christophe P Harmange

Peter Scott Dragovich

Brian K Albrecht

Alan G Olivero

Jianwen A Feng

Daniel Fred Ortwine

Chudi Obioma Ndubaku

Victor S Gehling

Alexander M Taylor

Sharada Shenvi Labadie

Steven F Bellon

Birong Zhang

Richard Pastor

Alexandre Cote

Zhiguo Liu

Yongsheng Chen

John Wai

Naomi Rajapaksa

Compounds of Formula I and methods of use as Interleukin-1 Receptor Associated Kinase 4 (IRAK4) inhibitors are described herein.

Pyrazolo[1,5a]pyrimidine derivatives as IRAK4 modulators

Compounds of Formula I, Formula II, Formula III, Formula IV, Formula V, Formula VI, Formula VII, Formula VIII, and methods of use as Interleukin-1 Receptor Associated Kinase (IRAK4) inhibitors are described herein.

Pyrazolo[ 1,5a]pyrimidine derivatives as IRAK4 modulators

Compounds of Formula 0, Formula I, and Formula II and methods of use as Interleukin-1 Receptor Associated Kinase (IRAK4) inhibitors are described herein.

Compounds of Formula 0, and stereoisomers and pharmaceutically acceptable salts thereof, as well as methods of use as Interleukin-1 Receptor Associated Kinase (IRAK4) inhibitors are described herein.

IRAK4 modulators

Provided are compounds useful as inhibitors of one or more histone demethylases, such as KDM5. The invention also provides pharmaceutically acceptable compositions comprising compounds of the present invention and methods of using the present composition in the treatment of various disorders.

Pyrazolo compounds and uses thereof

Growing community of inventors

South San Francisco, CA, United States of America

James Richard Kiefer, Jr